M. Létourneau

发表

Development and pharmacological characterization of “caged” urotensin II analogs

S. Bourgault, M. Létourneau, A. Fournier, 2005, Peptides.

Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide.

H. Vaudry, M. Létourneau, A. Fournier, 2012, Biochimica et biophysica acta.

The amidated PACAP1-23 fragment is a potent reduced-size neuroprotective agent.

T. Hébert, M. Létourneau, A. Fournier, 2019, Biochimica et biophysica acta. General subjects.

Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects.

H. Vaudry, S. Bourgault, M. Létourneau, 2011, Biochemical pharmacology.

Insight into the role of urotensin II‐related peptide tyrosine residue in UT activation

T. Hébert, M. Létourneau, D. Chatenet, 2017, Biochemical pharmacology.

Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

M. Létourneau, A. Fournier, J. Dupuis, 2012, Biochemical pharmacology.

Effectiveness of the suzuki-miyaura cross-coupling reaction for solid-phase peptide modification.

S. Bourgault, M. Létourneau, A. Fournier, 2008, Journal of combinatorial chemistry.

Cardiotoxin‐I: An Unexpectedly Potent Insulinotropic Agent

N. Doucet, B. Folch, M. Létourneau, 2012, Chembiochem : a European journal of chemical biology.

Identification of ETA and ETB binding domains using ET-derived photoprobes.

M. Létourneau, A. Fournier, Jacinthe Aubin, 2008, Biochimie.

Semi‐rational evolution of the 3‐(3‐hydroxyalkanoyloxy)alkanoate (HAA) synthase RhlA to improve rhamnolipid production in Pseudomonas aeruginosa and Burkholderia glumae

N. Doucet, M. Létourneau, Eric Déziel, 2019, The FEBS journal.

SPECT)ission computed tomography Physiological imaging of the lung

D. Bailey, M. Létourneau, A. Fournier, 2015 .

PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors

M. Létourneau, A. Fournier, M. Detheux, 2005, Peptides.

Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model

H. Vaudry, A. Couvineau, M. Létourneau, 2016, Neuropharmacology.

pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson ' s disease model

H. Vaudry, A. Couvineau, M. Létourneau, 2015 .

Genome sequencing and functional characterization of a Dictyopanus pusillus fungal enzymatic extract offers a promising alternative for lignocellulose pretreatment of oil palm residues

N. Doucet, A. T. Vincent, M. Létourneau, 2020, PloS one.

Genome sequencing and functional characterization of a Dictyopanus pusillus fungal extract offers a promising alternative for lignocellulose pretreatment of oil palm residues

N. Doucet, A. T. Vincent, M. Létourneau, 2019, bioRxiv.

Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart

M. Létourneau, A. Fournier, T. Nguyen, 2012, British journal of pharmacology.

PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool

M. Létourneau, A. Fournier, J. Dupuis, 2013, The Journal of Nuclear Medicine.

Study of solid-phase synthesis and purification strategies for the preparation of polyglutamine peptides.

M. Létourneau, A. Fournier, Y. Boulanger, 2007, Biopolymers.

Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial

M. Guertin, M. Létourneau, A. Fournier, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension

J. Tardif, M. Létourneau, A. Fournier, 2019, Scientific Reports.

Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine.

M. Létourneau, A. Fournier, J. Dupuis, 2011, Nuclear medicine and biology.

Molecular Imaging of the Human Pulmonary Vascular Endothelium Using an Adrenomedullin Receptor Ligand

M. Létourneau, A. Fournier, J. Dupuis, 2015, Molecular imaging.

Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging.

M. Létourneau, A. Fournier, J. Dupuis, 2009, European journal of pharmacology.

Use of Adrenomedullin Derivatives for Molecular Imaging of Pulmonary Circulation

M. Létourneau, A. Fournier, A. Caron, 2008, Journal of Nuclear Medicine.

Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation.

M. Létourneau, A. Fournier, D. Chatenet, 2012, The international journal of biochemistry & cell biology.

Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs

M. Létourneau, A. Fournier, J. Dupuis, 2016, EJNMMI Research.

Development of photolabile caged analogs of endothelin-1

S. Bourgault, M. Létourneau, A. Fournier, 2007, Peptides.

Development of agonists of endothelin‐1 exhibiting selectivity towards ETA receptors

M. Létourneau, A. Fournier, P. Lampron, 2003, British journal of pharmacology.

Insights into structural and dynamical changes experienced by human RNase 6 upon ligand binding.

P. Agarwal, D. Gagné, N. Doucet, 2020, Biochemistry.

Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

N. Doucet, B. Folch, M. Létourneau, 2013, Journal of medicinal chemistry.

Al[18F]F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation.

M. Létourneau, A. Fournier, J. DaSilva, 2018, Nuclear medicine and biology.

Tunable Surface Charge Enables the Electrostatic Adsorption-Controlled Release of Neuroprotective Peptides from a Hydrogel-Nanoparticle Drug Delivery System.

M. Shoichet, M. Létourneau, C. Morshead, 2022, ACS applied materials & interfaces.

A conserved SH3-like fold in diverse putative proteins tetramerizes into an oxidoreductase providing an antimicrobial resistance phenotype

J. Pelletier, C. Baron, N. Doucet, 2023, Philosophical Transactions of the Royal Society B.

Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity.

N. Doucet, B. Folch, M. Létourneau, 2014, Journal of medicinal chemistry.

Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin.

M. Létourneau, A. Castonguay, M. Haghdoost, 2017, European journal of medicinal chemistry.

Conformational exchange divergence along the evolutionary pathway of eosinophil-associated ribonucleases.

P. Agarwal, N. Doucet, M. Létourneau, 2023, Structure.

Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin

D. Gagné, N. Doucet, Y. St-Pierre, 2015, Oncotarget.

Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor.

D. Devost, T. Hébert, M. Létourneau, 2019, Biochimica et biophysica acta. General subjects.

Update on the urotensinergic system: new trends in receptor localization, activation, and drug design

M. Létourneau, A. Fournier, David Chatenet, 2012, Front. Endocrin..

The Expression of Multiple Connexins Throughout Spermatogenesis in the Rainbow Trout Testis Suggests a Role for Complex Intercellular Communication1

D. Cyr, C. Audet, M. Létourneau, 2007, Biology of reproduction.

Structural characterization and effects on corticosteroid secretion of endothelin-1 and endothelin-3 from the frog Rana ridibunda.

H. Vaudry, M. Létourneau, A. Fournier, 2000, Journal of molecular endocrinology.

Structural characterization and effects on corticosteroid secretion of endothelin-1 and endothelin-3 from the frog

H. Vaudry, M. Létourneau, J. Conlon, 2000 .

Structural characterization and e ﬀ ects on corticosteroid secretion of endothelin-1 and endothelin-3 from the frog Rana ridibunda

H. Vaudry, M. Létourneau, J. Conlon, 2000 .

Structural characterization and e ff ects on corticosteroid secretion of endothelin-1 and endothelin-3 from the frog Rana ridibunda

H. Vaudry, M. Létourneau, A. Fournier, 2000 .

Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity

M. Létourneau, J. Perreault, Eric Déziel, 2017, PloS one.

Molecular Imaging of Monocrotaline-Induced Pulmonary Vascular Disease with Radiolabeled Linear Adrenomedullin

M. Létourneau, A. Fournier, J. Dupuis, 2009, Journal of Nuclear Medicine.

Protein context shapes the specificity of SH3 domain-mediated interactions in vivo

C. Landry, Jean-Philippe Lambert, G. Gish, 2021, Nature Communications.

Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

A Fournier, M. Létourneau, A. Fournier, 2013, British journal of pharmacology.

PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension

J. Tardif, M. Létourneau, A. Fournier, 2019, Scientific Reports.

Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide.

H. Vaudry, N. Doucet, B. Folch, 2012, Journal of controlled release : official journal of the Controlled Release Society.

SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases.

M. Létourneau, A. Fournier, J. DaSilva, 2019, American journal of nuclear medicine and molecular imaging.

Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP.

H. Vaudry, A. Couvineau, S. Bourgault, 2011, Biochimie.

Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands

E. Novellino, A. Carotenuto, J. Tanny, 2021, The Journal of biological chemistry.

Membrane-tethered peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as allosteric biased ligands

E. Novellino, A. Carotenuto, J. Tanny, 2020, bioRxiv.

Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease.

M. Létourneau, A. Fournier, D. Vaudry, 2016, Biochimica et biophysica acta.

Perturbing dimer interactions and allosteric communication modulates the immunosuppressive activity of human galectin-7

F. Pucci, M. Rooman, N. Doucet, 2021, The Journal of biological chemistry.

Binding of a Soluble meso-Tetraarylporphyrin to Human Galectin-7 Induces Oligomerization and Modulates Its Pro-Apoptotic Activity.

A. Urvoas, J. Mahy, M. Cuneo, 2020, Biochemistry.

Photoreleasable ligands to study intracrine angiotensin II signalling

S. Nattel, N. Doucet, B. Folch, 2015, The Journal of physiology.

Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide

N. Doucet, M. Létourneau, Eric Déziel, 2018, PloS one.

New insights about the peculiar role of the 28–38 C‐terminal segment and some selected residues in PACAP for signaling and neuroprotection

D. Devost, T. Hébert, M. Létourneau, 2018, Biochemical pharmacology.

Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin

D. Gagné, N. Doucet, Y. St-Pierre, 2015, Oncotarget.

Conformational exchange divergence along the evolutionary pathway of eosinophil-associated ribonucleases.

P. Agarwal, N. Doucet, M. Létourneau, 2023, Structure.